ZBIO (Zenas BioPharma) Net Margin %: 0.00% (As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $25.79
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma Net Margin %?

Zenas BioPharma ZBIO +4.86% 12 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Zenas BioPharma ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Zenas BioPharma's Net Income for the three months ended in Mar. 2026 was $-80.99 Mil. Zenas BioPharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Zenas BioPharma's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Zenas BioPharma's Net Margin % or its related term are showing as below:


ZBIO's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Zenas BioPharma  (NAS:ZBIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Zenas BioPharma Net Margin % Related Terms

Zenas BioPharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma Net Margin % Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 -74.25 -3,139.76 -3,777.37

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -335.73 0.00 0.00 0.00 0.00

ZBIO vs MNKD, OLMA, AKTS: Net Margin % Comparison

For the Biotechnology subindustry, Zenas BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Net Margin % falls into.


ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zenas BioPharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-377.737/10
=-3,777.37 %

Zenas BioPharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-80.987/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Zenas BioPharma (ZBIO) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Zenas BioPharma and its competitors. According to the industry distribution chart, Zenas BioPharma ranks #999999 out of 946 companies in the Biotechnology industry.
Is Zenas BioPharma's Net Margin % too high?
Zenas BioPharma's current Net Margin % is 0.00%. Based on the distribution chart, Zenas BioPharma ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Net Margin % compare to MNKD and OLMA?
According to the Biotechnology industry distribution chart, Zenas BioPharma ranks #999999 out of 946 companies for Net Margin %. This places Zenas BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.79
Price